Notification of Publication of Corporate Communication on the Company's Website We hereby notify you that the following corporate communication (the "Current Corporate Communication") of Perfect Medical Health Management Limited (the "Company"), in both English and Chinese versions, are now available on the Company's website at www.perfectmedical.com and the website of Hong Kong Exchanges and Clearing Limited (the "HKEXnews website") at www.hkexnews.hk: • Interim Report 2025/2026 PERFECT MEDICAL HEALTH MANA ...

Core Viewpoint - Perfect Medical (01830.HK) reported a 21.7% decrease in revenue to HKD 486 million for the six months ending September 30, 2025, with a profit attributable to equity holders of HKD 94.8 million, reflecting a 32.7% decline year-on-year, although a 43.4% increase compared to the previous six-month period [1] Financial Performance - Revenue decreased by 21.7% to HKD 486 million [1] - Profit attributable to equity holders was HKD 94.8 million, down 32.7% year-on-year but up 43.4% from the previous six-month period [1] - Basic earnings per share were HKD 0.075 [1] - Proposed interim dividend is HKD 0.076 per share, with a payout ratio of 101.3% [1] - The company has maintained a payout ratio of 100% or above for eleven consecutive years [1] Market Environment - The core Hong Kong market continues to face structural challenges impacting discretionary spending in service categories [1] - Although overall retail sales have shown slight recovery since May 2025 due to inbound tourism, the recovery is primarily in retail goods rather than medical beauty services [1] - The increase in outbound travel and overseas spending by local residents has significantly affected the company's performance by draining discretionary income from the local service market [1] - A cooling labor market and changing consumer habits have led to a more cautious overall consumption sentiment, resulting in a noticeable decline in consumer willingness to spend on medical beauty and beauty services [1] - Multiple factors have temporarily limited revenue growth and significantly impacted the company's mid-term financial performance [1]

Core Viewpoint - Perfect Medical (01830) reported a significant decline in revenue and profit for the six months ending September 30, 2025, indicating potential challenges in its business operations [1] Financial Performance - Revenue decreased by 21.7% year-on-year to HKD 486 million [1] - Profit attributable to equity holders fell by 32.7% to HKD 94.8 million [1] - Basic earnings per share were HKD 0.075 [1] - The company proposed an interim dividend of HKD 0.076 per share [1]

EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | 股票發行人現金股息公告 | | | 發行人名稱 | 完美醫療健康管理有限公司 | | 股份代號 | 01830 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至二零二五年九月三十日止六個月的中期股息 | | 公告日期 | 2025年11月28日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 中期（半年期） | | 股息性質 | 普通股息 | | 財政年末 | 2026年3月31日 | | 宣派股息的報告期末 | 2025年9月30日 | | 宣派股息 | 每 股 0.076 HKD | | 股東批准日期 | 不適用 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.076 HKD | | 匯率 | 1 HK ...

Financial Performance - Revenue decreased by 21.7% to HKD 485.9 million[2] - Profit attributable to equity holders was HKD 94.8 million, down 32.7% year-on-year, but up 43.4% from the previous six-month period[2] - Basic earnings per share were HKD 0.075[3] - Total comprehensive income for the period was HKD 110.3 million, compared to HKD 160.3 million in the previous year[4] - Total revenue for the six months ended September 30, 2025, was HKD 485,880,000, a decrease of 21.6% from HKD 620,272,000 in the same period of 2024[12] - The net profit attributable to equity holders for the six months ended September 30, 2025, was HKD 94,804,000, down 32.8% from HKD 140,844,000 in the same period of 2024[19] - Basic earnings per share for the period was HKD 0.075, a decrease from HKD 0.112 in the previous year[19] - EBITDA decreased by 26.7% to HKD 142.2 million, with an EBITDA margin of 29.3%, down from 31.3% in the previous period[49] - Operating profit decreased by 30.0% to HKD 111.0 million, with an operating profit margin of 22.8%, down from 25.6%[49] Dividend Information - Proposed interim dividend is HKD 0.076 per share, with a payout ratio of 101.3%[2] - The company continues to maintain a dividend payout ratio of 100% or above for eleven consecutive years[2] - The board proposed an interim dividend of HKD 0.076 per share for the six months ended September 30, 2025, to be paid on or around December 31, 2025[73] Assets and Liabilities - Non-current assets decreased from HKD 464.3 million to HKD 417.1 million[5] - Current assets increased from HKD 471.6 million to HKD 508.3 million, with cash and cash equivalents rising to HKD 326.0 million[5] - Total equity increased from HKD 378.7 million to HKD 423.5 million[6] - Total liabilities decreased from HKD 557.2 million to HKD 501.9 million[6] - Non-current assets in Hong Kong totaled HKD 236,911,000, a decrease from HKD 274,354,000 as of March 31, 2025[12] - Non-current assets outside Hong Kong were HKD 62,139,000, down from HKD 79,417,000 as of March 31, 2025[12] - Cash and cash equivalents totaled HKD 326,007,000 as of September 30, 2025, compared to HKD 249,074,000 on March 31, 2025[28] Revenue Breakdown - Revenue from Hong Kong was HKD 386,847,000, down 22.3% from HKD 497,803,000 year-on-year[12] - Revenue from regions outside Hong Kong was HKD 99,033,000, a decrease of 19.1% compared to HKD 122,469,000 in the previous year[12] - Revenue from the Hong Kong market accounted for 79.6% of total revenue at HKD 386.8 million, while revenue from regions outside Hong Kong was HKD 99.0 million, representing 20.4% of total revenue[46] - Revenue declined by 22.3% year-on-year to HKD 386.8 million, but only a 2.3% decrease compared to the previous six months[52] - Revenue from operations outside Hong Kong amounted to HKD 99.0 million, accounting for 20.4% of the group's total revenue, down from HKD 122.5 million in the same period last year[56] Cost Management - Key cost components showed a significant reduction, with employee benefits expenses decreasing by 23.1% to HKD 167.2 million and marketing expenses down by 29.3% to HKD 54.6 million[47] - Cost optimization measures led to a 33.8% decrease in inventory and consumables costs to HKD 6.9 million, reflecting a decline in treatment volume and favorable supplier terms[48] - Employee benefits expenses decreased by 23.1% to HKD 167.2 million due to staff adjustments following center integration, ensuring service quality remained unaffected[48] - The group has implemented strict cost control measures to improve operational efficiency, which has helped maintain profit margins despite revenue declines[41][42] Strategic Initiatives - The group is focusing on enhancing customer retention and lifetime value in the mainland China market, rather than pursuing aggressive expansion strategies[40][41] - The group has transitioned several strategic initiatives, including the launch of cost-effective medical beauty services and digital marketing driven by artificial intelligence, from planning to implementation[44] - The company launched its first "Oracle" service center in October 2025, targeting tech-savvy millennials and Gen Z consumers with innovative skincare solutions[54] - The new flagship center in Tsim Sha Tsui successfully opened, enhancing customer traffic and average transaction value[51] - The group plans to enhance AI-driven marketing and digital capabilities, and cautiously expand complementary services such as Oracle and Goku Spa to attract new customers[71] Employee Information - The group employed a total of 840 employees as of September 30, 2025, down from 971 employees on March 31, 2025[66] Financial Position - The group maintained a strong financial position with bank balances and cash of HKD 425.0 million as of September 30, 2025, compared to HKD 394.6 million on March 31, 2025[58] - Net cash generated from operating activities was HKD 156.2 million, a decrease from HKD 203.4 million in the previous interim period[59] - Capital expenditures totaled HKD 14.9 million, primarily for lease renovations and equipment necessary for expanding the service network[60] Shareholder Information - The company had a total of 1,256,197,000 shares outstanding with a share premium of HKD 194,371,000 as of September 30, 2025[29] - Dr. Ouyang Jiang holds a beneficial interest in 114,834,747 shares, representing 75.18% of the shares he controls[76] - Sure Sino Investments Limited owns 459,739,481 shares, accounting for 36.59% of the total issued shares[82] - The company will suspend the registration of share transfers on December 16, 2025, to qualify for the interim dividend[75] Corporate Governance - The company has adhered to all provisions of the Corporate Governance Code during the reporting period, except for the combined roles of Chairman and CEO held by Dr. Ouyang Jiang[90] - The Audit Committee, established on December 5, 2011, is responsible for reviewing financial information and overseeing the financial reporting process[91] - The Remuneration Committee, also established on December 5, 2011, provides recommendations on the remuneration policies for all directors and senior management[92] - The Nomination Committee, formed on December 5, 2011, evaluates the independence of independent non-executive directors and reviews board diversity policies[93] - The board of directors includes executive directors Dr. Ouyang Jiang, Ms. Ouyang Hui, Ms. Ouyang Hong, and Mr. Su Xianlong, as well as independent non-executive directors Ms. Xu Huimin, Ms. Cao Yiping, Mr. Ji Zhixiong, and Mr. Qi Shichang[94]

Core Viewpoint - Perfect Medical (01830) expects a decrease in shareholder profit for the six months ending September 30, 2025, to approximately HKD 93 million to HKD 98 million, compared to HKD 141 million for the same period ending September 30, 2024, primarily due to the continued overseas travel of Hong Kong residents and a generally cautious consumer sentiment in the operating locations, leading to weakened consumer spending [1] Group 1 - The expected profit for the six months ending September 30, 2025, is projected to be around HKD 93 million to HKD 98 million [1] - The profit for the same period ending September 30, 2024, was HKD 141 million [1] - The decrease in profit is attributed to the ongoing overseas travel of Hong Kong residents [1] Group 2 - The overall consumer sentiment in the operating locations is described as generally cautious [1] - This cautious sentiment has resulted in weakened consumer spending [1]

Core Viewpoint - Perfect Medical (01830) anticipates a decrease in shareholders' profit for the six months ending September 30, 2025, to approximately HKD 93 million to HKD 98 million, down from HKD 141 million for the same period ending September 30, 2024, primarily due to the ongoing overseas travel by Hong Kong residents and a generally cautious consumer sentiment in the operating locations, leading to weakened consumer spending [1] Summary by Relevant Categories Financial Performance - Expected shareholders' profit for the six months ending September 30, 2025, is projected to be around HKD 93 million to HKD 98 million [1] - This represents a significant decrease from HKD 141 million for the same period in 2024 [1] Market Conditions - The decline in profit is attributed to the continued overseas travel of Hong Kong residents [1] - There is a prevailing cautious consumer sentiment in the locations where the group operates, contributing to reduced consumer spending [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 PERFECT MEDICAL HEALTH MANAGEMENT LIMITED 完美醫療健康管理有限公司 （於開曼群島註冊成立之有限公司） （股份代號：1830） 盈利預告 補充公佈 董事會謹此進一步知會股東及潛在投資者，截至二零二五年九月三十日止六個月之股東應 佔溢利預期將減少至約93百萬港元至98百萬港元（而截至二零二四年九月三十日止六個月 則為141百萬港元）的根本原因。溢利減少主要歸因於香港居民持續外遊及集團經營的所在 地消費氣氛普遍審慎，導致消費開支減弱。 – 1 – 本公佈所載資料乃基於對本集團未經審核綜合管理賬目進行之初步評估，並可能作出調 整。本公司正在落實其截至二零二五年九月三十日止六個月之中期業績，而中期業績預期 將於二零二五年十一月二十八日公佈。 本公司股東及潛在投資者切記避免過份倚賴該等資料，於買賣本公司股份時亦請審慎行 事。 本公佈乃完美醫療健康管理有限公司（「本公司」，連 ...

Core Viewpoint - Perfect Medical (01830) anticipates a shareholder profit of approximately HKD 93 million to HKD 98 million for the six months ending September 30, 2025, compared to HKD 141 million for the six months ending September 30, 2024, indicating a significant growth trajectory in profitability [1] Financial Performance - The expected shareholder profit for the period ending September 30, 2025, is projected to be between HKD 93 million and HKD 98 million [1] - For the six months ending September 30, 2024, the recorded shareholder profit was HKD 141 million [1] - The anticipated profit for the period ending September 30, 2025, represents an increase of at least 40% compared to the approximately HKD 66 million profit recorded in the second half of the 2025 fiscal year [1]

Group 1 - The company, Perfect Medical (01830.HK), expects a profit attributable to shareholders of approximately HKD 93 million to HKD 98 million for the six months ending September 30, 2025 [1] - For the six months ending September 30, 2024, the company recorded a profit attributable to shareholders of HKD 141 million [1] - The expected profit for the period is projected to increase by no less than 40% compared to approximately HKD 66 million recorded in the second half of the fiscal year 2025 [1]